


Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline
Strengthening of strategic option license agreement to cover…

Destiny Pharma plc – Dr Debra Barker Appointed Interim CEO
Brighton, United Kingdom – 25th May 2023: Destiny Pharma…

Verona Pharma to Present at Jefferies Healthcare Conference
LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona…

InProTher announces EUR 6MSeed financing with the participation of the European Innovation Council Fund to develop first-in-class cancer immunotherapy
• Danish start-up developing immunotherapies designed to fight…

Poolbeg Pharma Plc – Board Appointment
24 May 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg'…

Vicore obtains significant new patent protection for C21 in the US
Stockholm, May 23, 2023 – Vicore Pharma Holding AB (STO:VICO)…

Scarlet Therapeutics Announces Seed Financing to Advance Development of Therapeutic Red Blood Cell Platform
Pioneering platform to generate novel therapies with potential…

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors
Leading medical oncologist and seasoned biotechnology executive…

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D’Andrea to its Board of Directors
Leading industry expert with more than 25 years of experience…

Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023
First-in-class, cardioprotective drug with potential to transform…

Vicore reports new 36-week data from the AIR trial demonstrating sustained disease stabilization and increase in lung function in IPF patients
Stockholm, May 19, 2023 – Vicore Pharma Holding AB (publ)…

AMSilk to join panel at SynBioBeta Global Synthetic Biology Conference
Munich, Germany, 17 May, 2023: AMSilk GmbH (“AMSilk”), the…

Vicore to host webcast with updated AIR trial results after presentation at the ATS congress
Webcast to be held on: May 26, 2023 at 08:00 EST/14:00 CET
Stockholm,…

Peer-Reviewed Translational Research Paves The Way For First-In-Class Autotaxin Inhibitor IOA-289 In Cancer
Amsterdam, The Netherlands and Geneva, Switzerland, 16 May 2023 -…

Acesion Pharma Announces Positive Pre-Clinical Data for AP31969
Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the…

Optimum Hires Senior Journalist Stephen Adams, Former Medical Editor of The Mail on Sunday
London, UK, 15 May 2023 – Optimum Strategic Communications…

Vicore strengthens its Board of Directors
Stockholm, May 12, 2023 – Vicore Pharma Holding AB (STO: VICO)…

BII appointed by the Danish government to run international deep tech start-up accelerator
BioInnovation Institute (BII), an international non-profit foundation…

UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer
UCB’s expertise in macrocyclic peptide discovery, using…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York